CareDx Shares Trade Up 15% After Announcing 57% YoY Increase in Q3 Revenue
Source: Streetwise Reports  (10/8/20)
CareDx shares established a new 52-week high after the company reported that preliminary revenue in Q3/20 increased 57% year-over-year to $53.0 million. More >

StreetSmart Live! Presents Algernon Pharmaceuticals
Source: Streetwise Reports  (10/8/20)
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
More >

Immunotherapy Firm Announces Positive Top-Line Trial Results for Severe and Critical COVID-19 Patients
Source: Streetwise Reports  (10/7/20)
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report. More >

Creator of Antibiotic-Free Livestock Supplement Extends Reach in Mexico
Source: Streetwise Reports  (10/7/20)
Avivagen reports that it has gained both new customers and increased access to prospective ones. More >

Ocular Therapeutix Shares Rise 25% After Firm Reports 250% Sequential Increase in Q3 Revenue
Source: Streetwise Reports  (10/7/20)
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter. More >

Biopharma's Multinational COVID-19 Study Hits 75% Enrollment Mark
Source: Streetwise Reports  (10/5/20)
Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end. More >

MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb
Source: Streetwise Reports  (10/5/20)
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash. More >

American Renal Associates Agrees to Private Equity Firm's $853 Million Buyout Offer
Source: Streetwise Reports  (10/2/20)
Shares of American Renal Associates traded 67% higher and set a new 52-week high after the company reported that it has entered into a definitive agreement to be acquired by a Nautic Partners LLC affiliate for $11.50 per share in cash. More >

CloudMD: The Best Bet in Telehealth?
Source: Peter Epstein for Streetwise Reports  (10/1/20)
Peter Epstein of Epstein Research reviews the reasons he believes CloudMD is poised for substantial growth compared to peers. More >

AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm
Source: Streetwise Reports  (10/1/20)
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis. More >

Coverage Initiated on Telemedicine Firm in 'Strong Position for Long-Term Growth'
Source: Streetwise Reports  (9/30/20)
The investment thesis for CloudMD Software & Services is presented in a Mackie Research Capital Corp. report. More >

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial
Source: Streetwise Reports  (9/30/20)
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. More >

Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (9/30/20)
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. More >

Genetron Receives FDA Breakthrough Approval for Hepatocellular Carcinoma Detection Device
Source: Streetwise Reports  (9/30/20)
Genetron Holdings Ltd. shares traded 25% higher after the company reported it has received Breakthrough Device Designation from the FDA for its blood-based next-generation sequencing test for early hepatocellular carcinoma detection. More >

Aptorum Shares Skyrocket Upon Launching Infectious Disease Liquid Biopsy Unit
Source: Streetwise Reports  (9/29/20)
Shares of Aptorum Group Ltd. traded nearly 300% higher after the company reported it launched an infectious disease liquid biopsy start-up subsidiary. More >

GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test
Source: Streetwise Reports  (9/28/20)
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. More >

Owens & Minor Shares Climb 50% after Raising FY/20 Earnings Guidance by 66%
Source: Streetwise Reports  (9/24/20)
Shares of Owens & Minor Inc. reached a new 52-week high after the company raised FY/20 earnings guidance by 66% and advised it expects the positive earnings trend to continue in 2021. More >

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study
Source: Streetwise Reports  (9/23/20)
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. More >

California-Based Biotech Receives COVID-19 Trial Clearance
Source: Streetwise Reports  (9/23/20)
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. More >

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens
Source: Streetwise Reports  (9/23/20)
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. More >

AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study
Source: Streetwise Reports  (9/22/20)
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. More >

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients
Source: Streetwise Reports  (9/21/20)
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. More >

Biopharma Advances Development of Psilocybin-Based Therapeutics
Source: Streetwise Reports  (9/21/20)
Revive Therapeutics provides an update on its psychedelics therapeutics programs. More >

Pharma Greenlighted to Continue Multinational COVID-19 Study
Source: Streetwise Reports  (9/18/20)
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. More >

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19
Source: Streetwise Reports  (9/17/20)
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. More >